Episode Details

Send us Fan Mail

Cancer doesn’t just grow, it learns. Joe Grumbine and Dr. Robert Hoffman dig into a hard truth that too many patients discover late: tumors can change their behavior, their markers, and their vulnerabilities, even when a treatment plan looks “stable” on paper. We start with what sparked the conversation, a metastatic breast cancer case where old numbers look fine and a new number shifts, then use that as a launch point for how cancer adapts over time.

We unpack why drug resistance can emerge after long stretches on the same therapy, why “recurrence” may be better understood as cancer regrouping, and how that changes the way you think about timing, sequencing, and strategy. Dr. Hoffman explains methionine dependence, methionine restriction, and oral methioninase, with a clear warning against naive single-solution thinking. We also get into adaptive therapy concepts like cycling treatment, plus the real-world tools that help you stay ahead: PET CT and other imaging, cancer-specific blood markers, and the growing role of circulating tumor DNA and circulating tumor cells in precision oncology.

We also talk nuts and bolts that matter in daily life: why comparing lab results across different labs can mislead, how insurance realities shape testing, and why off-label targeted therapy is often just common sense when the genetic target matches. The conversation touches on emerging and controversial areas too, including ivermectin research signals and why intravenous vitamin C alongside chemo keeps coming up in clinical data conversations.

If you want a practical, clear-eyed framework for long-term cancer surveillance and personalized cancer care, press play. Subscribe, share this with someone who needs a smarter plan, and leave a review with your biggest question about monitoring or resistance.

Intro for podcast

information about subscriptions

Support the show

Support for Joe's Cure

Here is the link for Sunday's 4 pm Pacific time Zoom meeting